1. Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer
   Fang Liang et al, 2021, Experimental Biology and Medicine CrossRef
2. Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review
   Haller J. Smith et al, 2017, Gynecologic Oncology Reports CrossRef
3. Aberrant promoter methylation of cancer-related genes in human breast cancer
   Liang Wu et al, 2016, Oncology Letters CrossRef
4. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors
   Moustafa M. Madkour et al, 2023, Annals of Medicine CrossRef
5. DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome
   Howard L Ribeiro et al, 2017, Journal of Clinical Pathology CrossRef
6. Detection of hypermethylation BRCA1/2 gene promoter in breast tumours among Moroccan women
   Imane Saif et al, 2021, Molecular Biology Reports CrossRef
7. Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women
   Nisreen Al-Moghrabi et al, 2024, International Journal of Molecular Sciences CrossRef
8. Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers
   Emmanuel B. Omole et al, 2022, Cancers CrossRef
9. Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review
   Lorena Alves Teixeira et al, 2020, Journal of Clinical Pathology CrossRef
10. BRCA1 promoter hypermethylation in human placenta: a hidden link with β-hCG expression
    Revathy Nadhan et al, 2020, Carcinogenesis CrossRef
11. Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management
    Mohammad Aslam Khan et al, 2021, Seminars in Cancer Biology CrossRef
12. Immunohistochemical expression of DNA methyltransferases 1, 3a, and 3b in actinic cheilitis and lip squamous cell carcinomas
    Filipe I. Daniel et al, 2016, Journal of Oral Pathology & Medicine CrossRef
13. Current data and future perspectives on DNA methylation in ovarian cancer (Review)
    Mengyu Fu et al, 2024, International Journal of Oncology CrossRef
14. Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
    Roshni D. Kalachand et al, 2020, Obstetrics & Gynecology Science CrossRef
15. BRCA1Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
    Roshni D Kalachand et al, 2020, JNCI: Journal of the National Cancer Institute CrossRef
16. Evaluation of promoter hypermethylation of tumor suppressor gene BRCA1 in epithelial ovarian cancer
    DnyaneshB Amle et al, 2022, Journal of Cancer Research and Therapeutics CrossRef
17. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
    Hisamitsu Takaya et al, 2020, Scientific Reports CrossRef
18. Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines
    Biji Chatterjee et al, 2019, BioFactors CrossRef
19. Methylation Status and Immunohistochemistry of BRCA1 in Epithelial Ovarian Cancer
    Heru Pradjatmo et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef
20. ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer
    Arun Kanakkanthara et al, 2019, Nature Communications CrossRef